(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2013 (31.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/160873 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) *A61P 3/00* (2006.01)
A61K 31/422 (2006.01) *A61P 3/04* (2006.01)
A61K 31/4245 (2006.01) *A61P 3/10* (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:
PCT/IB2013/053292

(22) International Filing Date:
25 April 2013 (25.04.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/639,341 27 April 2012 (27.04.2012) US
PCT/CN2013/072735 15 March 2013 (15.03.2013) CN
61/787,695 15 March 2013 (15.03.2013) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants *(for US only)*: **CHEN, Xin** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **DING, Yiping** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **DUVADIE, Rohit** [US/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **GAI, Yu** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **HARRISON, Tyler** [CA/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **LIU, Qian** [US/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **LARROW, Jay** [US/US]; Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **MAO, Justin Yik Ching** [CA/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **PATEL, Sejal** [US/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **YE, Jiong** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **ZECRI, Frederic** [FR/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **ZHENG, Xuchun** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **ZHENG, Rui** [CN/US]; Novartis Institutes for Biomedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **ZHOU, Yizong** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: CYCLIC BRIDGEHEAD ETHER DGAT1 INHIBITORS



(I)

(57) Abstract: The invention relates to compounds of formula (I): (I) useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

WO 2013/160873 A1

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*